NASDAQ:BCTX

Briacell Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy BCTX

*Your capital is at risk

$3.31

+0.0400 (+1.22%)

At Close: Jun 03, 2026

BriaCell Therapeutics Stock Insider Power

Based on the 60 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 6.18M and sold 0 BCTX shares in the last 60 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 60 transactions)	0
● Buy	6.18M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2024 Buy	Common Shares P-Purchase	Lustig Marc	Director	902 935 Value: $2.00M
May 14, 2024 Buy	Common Stock Warrants P-Purchase	Lustig Marc	Director	902 935 Value: $1.91M
May 14, 2024 Buy	Common Stock Warrants P-Purchase	Lustig Marc	Director	902 935 Value: $1.91M
May 14, 2024 Buy	Common Shares P-Purchase	Lustig Marc	Director	902 935 Value: $2.00M
Dec 28, 2022 Buy	Common Shares P-Purchase	Bondarenko Jamieson Chairman	CEO / President	28 000 Value: $128.2K
Dec 28, 2022 Buy	Common Shares P-Purchase	Bondarenko Jamieson Chairman	CEO / President	28 000 Value: $128.2K
Dec 23, 2022 Buy	Warrant P-Purchase	Williams William V. President, CEO	CEO / President	2 530 Value: $5K
Dec 23, 2022 Buy	Warrant P-Purchase	Williams William V. President, CEO	CEO / President	2 530 Value: $5K
Dec 20, 2022 Buy	Common Shares P-Purchase	Bondarenko Jamieson Director	Director	22 000 Value: $117.7K
Dec 20, 2022 Buy	Common Shares P-Purchase	Bondarenko Jamieson Director	Director	22 000 Value: $117.7K
Aug 01, 2022 Buy	Option (Right to Buy)	Bondarenko Jamieson Director	Director	250 000 Value: $2.12M
Aug 01, 2022 Buy	Common Shares	Bondarenko Jamieson Director	Director	0 Value: $0
Aug 01, 2022 Buy	Common Shares	Bondarenko Jamieson Director	Director	0 Value: $0
Aug 01, 2022 Buy	Option (Right to Buy)	Bondarenko Jamieson Director	Director	250 000 Value: $2.12M
Aug 01, 2022 Buy	Common Shares	Lustig Marc Director	Director	0 Value: $0
Aug 01, 2022 Buy	Common Shares	Lustig Marc Director	Director	0 Value: $0
Aug 01, 2022 Buy	Option (Right to Buy)	Williams Williams V. President & CEO	CEO / President	22 300 Value: $188.9K
Aug 01, 2022 Buy	Option (Right to Buy)	Gross Jane A Director	Director	50 000 Value: $423.5K
Aug 01, 2022 Buy	Common Shares	Levin Gadi CFO & Secretary	C-Suite Officer	0 Value: $0
Aug 01, 2022 Buy	Option (Right to Buy)	Levin Gadi CFO & Secretary	C-Suite Officer	20 000 Value: $94.2K
Aug 01, 2022 Buy	Option (Right to Buy)	Schmieg Martin E. Director	Director	50 000 Value: $423.5K
Aug 01, 2022 Buy	Common Shares	Schmieg Martin E. Director	Director	0 Value: $0
Aug 01, 2022 Buy	Stock Option	Lopez-lago Miguel A. Chief Scientific Officer	Officer	15 000 Value: $127.1K
Aug 01, 2022 Buy	Common Shares	Embro-pantalony Vaughn C. Director	Director	0 Value: $0
Aug 01, 2022 Buy	Option (Right to Buy)	Taub Rebecca Director	Director	10 000 Value: $84.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BRIACELL THERAPEUTICS CORP.

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immun...

Read Full Profile Here